International specialty healthcare company Swedish Orphan Biovitrum (STO: SOBI) has gained commercial rights for Relistor, Deflux and Solestal from PharmaSwiss, it has been announced.
Under the agreement, SOBI will have the right to distribute the drugs in a territory including western Europe, Czech Republic, Slovakia, Hungary and, for Relistor, in Russia.
Alan Raffensperger, senior vice president and chief operating officer at SOBI, said: “I am delighted that we have expanded our successful partnership with PharmaSwiss to provide patients and physicians with additional treatment options that address unmet medical needs in each specific therapeutic category.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze